Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes

References

• KnowlesMRDuriePRWhat is cystic fibrosis?N Engl J Med2002347643944212167688
   PubMed Web of Science ®Google Scholar
• SantisGBasic molecular geneticsHodsonMEGeddesDMCystic FibrosisLondon, UKChapman & Hall19951534
   Google Scholar
• RaidtLIdelevichEADubbersAIncreased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decadePediatr Infect Dis J201534770070525851069
   PubMed Web of Science ®Google Scholar
• DoringGConwaySPHeijermanHGAntibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensusEur Respir J200016474976711106223
   PubMed Web of Science ®Google Scholar
• DoringGFlumePHeijermanHElbornJSTreatment of lung infection in patients with cystic fibrosis: current and future strategiesJ Cyst Fibros201211646147923137712
   PubMed Web of Science ®Google Scholar
• CooneyGFLumBLTomaselliMFielSBAbsolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosisJ Clin Pharmacol19943432552598021334
   PubMed Web of Science ®Google Scholar
• GellerDEPitlickWHNardellaPATracewellWGRamseyBWPharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosisChest2002122121922612114362
   PubMed Web of Science ®Google Scholar
• FlumePAO’SullivanBPRobinsonKACystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung healthAm J Respir Crit Care Med20071761095796917761616
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document for Anti-Infective Drugs Advisory Committee MeetingAztreonam for inhalation solution (NDA 50-814) for improvement of respiratory symptoms in cystic fibrosis patients 2009 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM193023.pdfAccessed June 1, 2015
   Google Scholar
• Cystic Fibrosis FoundationDrug Development Pipeline2015 Available from: http://www.cff.org/research/DrugDevelopmentPipeline/Accessed June 1, 2015
   Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• AbbottJDoddMBiltonDWebbAKTreatment compliance in adults with cystic fibrosisThorax19944921151208128399
   PubMed Web of Science ®Google Scholar
• ConwaySPPondMNHamnettTWatsonACompliance with treatment in adult patients with cystic fibrosisThorax199651129338658364
   PubMed Web of Science ®Google Scholar
• BenderBGMotivating patient adherence to allergic rhinitis treatmentsCurr Allergy Asthma Rep20151531025956611
   PubMed Web of Science ®Google Scholar
• ChanAHStewartAWHarrisonJCamargoCAJrBlackPNMitchellEAThe effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trialLancet Respir Med20153321021925617215
   PubMed Web of Science ®Google Scholar
• Arias LlorenteRPBousono GarciaCDiaz MartinJJTreatment compliance in children and adults with cystic fibrosisJ Cyst Fibros20087535936718304896
   PubMed Web of Science ®Google Scholar
• WhiteTMillerJSmithGLMcMahonWMAdherence and psychopathology in children and adolescents with cystic fibrosisEur Child Adolesc Psychiatry20091829610418807223
   PubMed Web of Science ®Google Scholar
• WhiteRGHakimAJSalganikMJStrengthening the reporting of observational studies in epidemiology for respondent-driven sampling studies: “STROBE-RDS” statementJ Clin Epidemiol201568121463147126112433
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementAnn Intern Med20091514264269 W26419622511
   PubMed Web of Science ®Google Scholar
• GellerDEFlumePAStaabDLevofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosaAm J Respir Crit Care Med2011183111510151621471106
   PubMed Web of Science ®Google Scholar
• RegnaultABalpMMKulichKViala-DantenMValidation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosisJ Cyst Fibros201211649450122583743
   PubMed Web of Science ®Google Scholar
• RamseyBWPepeMSQuanJMIntermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study GroupN Engl J Med1999340123309878641
   PubMed Web of Science ®Google Scholar
• HarrisonMJMcCarthyMFlemingCInhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF)J Cyst Fibros201413669269824815094
   PubMed Web of Science ®Google Scholar
• ModiACLimCSYuNGellerDWagnerMHQuittnerALA multi-method assessment of treatment adherence for children with cystic fibrosisJ Cyst Fibros20065317718516679071
   PubMed Web of Science ®Google Scholar
• OermannCMRetsch-BogartGZQuittnerALAn 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosisPediatr Pulmonol201045111121113420672296
   PubMed Web of Science ®Google Scholar
• BriesacherBAQuittnerALSaimanLSaccoPFouayziHQuittellLMAdherence with tobramycin inhaled solution and health care utilizationBMC Pulm Med201111521251275
   PubMed Web of Science ®Google Scholar
• EakinMNBilderbackABoyleMPMogayzelPJRiekertKALongitudinal association between medication adherence and lung health in people with cystic fibrosisJ Cyst Fibros201110425826421458391
   PubMed Web of Science ®Google Scholar
• McNamaraPSMcCormackPMcDonaldAJHeafLSouthernKWOpen adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosisJ Cyst Fibros20098425826319447080
   PubMed Web of Science ®Google Scholar
• WertzDAChangCLStephensonJJZhangJKuhnRJEconomic impact of tobramycin in patients with cystic fibrosis in a managed care populationJ Med Econ201114675976821942462
   PubMedGoogle Scholar
• AppelGBAminoglycoside nephrotoxicityAm J Med19908816S20S discussion 38S–42S2180292
   PubMed Web of Science ®Google Scholar
• ChuchalinAAmelinaEBiancoFTobramycin for inhalation in cystic fibrosis: beyond respiratory improvementsPulm Pharmacol Ther200922652653219616111
   PubMed Web of Science ®Google Scholar
• HilliardMEHahnARidgeAKEakinMNRiekertKAUser preferences and design recommendations for an mHealth app to promote cystic fibrosis self-managementJMIR Mhealth Uhealth201424e4425344616
   PubMed Web of Science ®Google Scholar